Flecainide

300 interactions 706 cited references

Also sold as: Tambocor®

About Flecainide

Flecainide is an antiarrhythmic medication used to prevent certain life-threatening irregular heartbeats. Read the full Flecainide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Pimozide Ritonavir Mesoridazine Piperaquine Nirmatrelvir Mavorixafor

18 Contraindicated 270 Major 11 Moderate 1 Minor

All (300) Contraindicated (18) Major (270) Moderate (11) Minor (1)

Major

Flecainide Amitriptyline Elavil An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Sertraline An increased risk of QT interval prolongation, an increased flecainide exposure and risk for toxicity (cardiac arrhythmia) Details Flecainide Buprenorphine Belbuca An increased risk of QT interval prolongation Details Flecainide Relugolix Orgovyx Increased risk of QT interval prolongation Details Flecainide Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Flecainide Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Flecainide Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Asenapine Transdermal Patch Secuado Increased flecainide exposure, an increased asenapine exposure, an increased risk of QT interval prolongation and an increased ris... Details Flecainide Azathioprine Azasan An increased risk of hepatotoxicity Details Flecainide Azithromycin AzaSite An increased risk of QT interval prolongation Details Flecainide Abiraterone Abirtega Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Flecainide Alfuzosin UroXatral An increased risk of QT interval prolongation Details Flecainide Anagrelide Agrylin Increased risk of QT interval prolongation Details Flecainide Bedaquiline Sirturo Increased risk of QT interval prolongation Details Flecainide Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Dacomitinib Vizimpro Increased exposure of the CYP2D6 substrate Details Flecainide Dasatinib Phyrago An increased risk of QT interval prolongation Details Flecainide Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Flecainide Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Flecainide Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Dofetilide Tikosyn An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Dolasetron Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Dolasetron Injection Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Encorafenib Braftovi Increased risk of QT interval prolongation Details Flecainide Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Flecainide Abiraterone Acetate Abirtega Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Flecainide Abiraterone Acetate, Micronized Abirtega Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Flecainide Acecainide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Adagrasib Krazati An increased risk of QT interval prolongation, increased exposure to CYP2D6 substrates Details Flecainide Ajmaline An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Amiodarone Nexterone Increased antiarrhythmic levels, QTc prolongation Details Flecainide Amisulpride Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Flecainide Amoxapine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Apomorphine Apokyn An increased risk of QT interval prolongation Details Flecainide Aprindine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Arbutamine An increased risk of cardiac arrhythmias Details Flecainide Aripiprazole Abilify An increased risk of QT interval prolongation Details Flecainide Aripiprazole Lauroxil Aristada An increased risk of QT interval prolongation Details Flecainide Artemether An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.